The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Human Respiratory Syncytial Virus Drugs Market Research Report 2024
Synopsis
Human respiratory syncytial virus (HRSV) is a syncytial virus that causes respiratory tract infections. It is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood. A prophylactic medication, palivizumab, can be employed to prevent HRSV in preterm (under 35 weeks gestation) infants, infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD), and infants with congenital malformations of the airway. Treatment is limited to supportive care, including oxygen therapy and more advanced breathing support with CPAP or nasal high flow oxygen.
The global Human Respiratory Syncytial Virus Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Human Respiratory Syncytial Virus Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Respiratory Syncytial Virus Drugs.
Report Scope
The Human Respiratory Syncytial Virus Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Respiratory Syncytial Virus Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Respiratory Syncytial Virus Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
AbbVie
GSK
Teva Pharmaceutical
Segment by Type
Approved Drugs
Off-Label Drugs
Segment by Application
Clinical Diagnostic
Laboratories Physicians' Office
Laboratories Hospitals
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Respiratory Syncytial Virus Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Respiratory Syncytial Virus Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Human respiratory syncytial virus (HRSV) is a syncytial virus that causes respiratory tract infections. It is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood. A prophylactic medication, palivizumab, can be employed to prevent HRSV in preterm (under 35 weeks gestation) infants, infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD), and infants with congenital malformations of the airway. Treatment is limited to supportive care, including oxygen therapy and more advanced breathing support with CPAP or nasal high flow oxygen.
The global Human Respiratory Syncytial Virus Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Human Respiratory Syncytial Virus Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Respiratory Syncytial Virus Drugs.
Report Scope
The Human Respiratory Syncytial Virus Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Respiratory Syncytial Virus Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Respiratory Syncytial Virus Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
AbbVie
GSK
Teva Pharmaceutical
Segment by Type
Approved Drugs
Off-Label Drugs
Segment by Application
Clinical Diagnostic
Laboratories Physicians' Office
Laboratories Hospitals
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Respiratory Syncytial Virus Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Respiratory Syncytial Virus Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Human Respiratory Syncytial Virus Drugs Market Overview
1.1 Product Overview and Scope of Human Respiratory Syncytial Virus Drugs
1.2 Human Respiratory Syncytial Virus Drugs Segment by Type
1.2.1 Global Human Respiratory Syncytial Virus Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Approved Drugs
1.2.3 Off-Label Drugs
1.3 Human Respiratory Syncytial Virus Drugs Segment by Application
1.3.1 Global Human Respiratory Syncytial Virus Drugs Market Value by Application: (2024-2030)
1.3.2 Clinical Diagnostic
1.3.3 Laboratories Physicians' Office
1.3.4 Laboratories Hospitals
1.4 Global Human Respiratory Syncytial Virus Drugs Market Size Estimates and Forecasts
1.4.1 Global Human Respiratory Syncytial Virus Drugs Revenue 2019-2030
1.4.2 Global Human Respiratory Syncytial Virus Drugs Sales 2019-2030
1.4.3 Global Human Respiratory Syncytial Virus Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Human Respiratory Syncytial Virus Drugs Market Competition by Manufacturers
2.1 Global Human Respiratory Syncytial Virus Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Human Respiratory Syncytial Virus Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Human Respiratory Syncytial Virus Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Human Respiratory Syncytial Virus Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Respiratory Syncytial Virus Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Respiratory Syncytial Virus Drugs, Product Type & Application
2.7 Human Respiratory Syncytial Virus Drugs Market Competitive Situation and Trends
2.7.1 Human Respiratory Syncytial Virus Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Human Respiratory Syncytial Virus Drugs Players Market Share by Revenue
2.7.3 Global Human Respiratory Syncytial Virus Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Respiratory Syncytial Virus Drugs Retrospective Market Scenario by Region
3.1 Global Human Respiratory Syncytial Virus Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Human Respiratory Syncytial Virus Drugs Global Human Respiratory Syncytial Virus Drugs Sales by Region: 2019-2030
3.2.1 Global Human Respiratory Syncytial Virus Drugs Sales by Region: 2019-2024
3.2.2 Global Human Respiratory Syncytial Virus Drugs Sales by Region: 2025-2030
3.3 Global Human Respiratory Syncytial Virus Drugs Global Human Respiratory Syncytial Virus Drugs Revenue by Region: 2019-2030
3.3.1 Global Human Respiratory Syncytial Virus Drugs Revenue by Region: 2019-2024
3.3.2 Global Human Respiratory Syncytial Virus Drugs Revenue by Region: 2025-2030
3.4 North America Human Respiratory Syncytial Virus Drugs Market Facts & Figures by Country
3.4.1 North America Human Respiratory Syncytial Virus Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Human Respiratory Syncytial Virus Drugs Sales by Country (2019-2030)
3.4.3 North America Human Respiratory Syncytial Virus Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Respiratory Syncytial Virus Drugs Market Facts & Figures by Country
3.5.1 Europe Human Respiratory Syncytial Virus Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Human Respiratory Syncytial Virus Drugs Sales by Country (2019-2030)
3.5.3 Europe Human Respiratory Syncytial Virus Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Respiratory Syncytial Virus Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Human Respiratory Syncytial Virus Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Human Respiratory Syncytial Virus Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Human Respiratory Syncytial Virus Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Respiratory Syncytial Virus Drugs Market Facts & Figures by Country
3.7.1 Latin America Human Respiratory Syncytial Virus Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Human Respiratory Syncytial Virus Drugs Sales by Country (2019-2030)
3.7.3 Latin America Human Respiratory Syncytial Virus Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Respiratory Syncytial Virus Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Respiratory Syncytial Virus Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Human Respiratory Syncytial Virus Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Human Respiratory Syncytial Virus Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Human Respiratory Syncytial Virus Drugs Sales by Type (2019-2030)
4.1.1 Global Human Respiratory Syncytial Virus Drugs Sales by Type (2019-2024)
4.1.2 Global Human Respiratory Syncytial Virus Drugs Sales by Type (2025-2030)
4.1.3 Global Human Respiratory Syncytial Virus Drugs Sales Market Share by Type (2019-2030)
4.2 Global Human Respiratory Syncytial Virus Drugs Revenue by Type (2019-2030)
4.2.1 Global Human Respiratory Syncytial Virus Drugs Revenue by Type (2019-2024)
4.2.2 Global Human Respiratory Syncytial Virus Drugs Revenue by Type (2025-2030)
4.2.3 Global Human Respiratory Syncytial Virus Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Human Respiratory Syncytial Virus Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Human Respiratory Syncytial Virus Drugs Sales by Application (2019-2030)
5.1.1 Global Human Respiratory Syncytial Virus Drugs Sales by Application (2019-2024)
5.1.2 Global Human Respiratory Syncytial Virus Drugs Sales by Application (2025-2030)
5.1.3 Global Human Respiratory Syncytial Virus Drugs Sales Market Share by Application (2019-2030)
5.2 Global Human Respiratory Syncytial Virus Drugs Revenue by Application (2019-2030)
5.2.1 Global Human Respiratory Syncytial Virus Drugs Revenue by Application (2019-2024)
5.2.2 Global Human Respiratory Syncytial Virus Drugs Revenue by Application (2025-2030)
5.2.3 Global Human Respiratory Syncytial Virus Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Human Respiratory Syncytial Virus Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Corporation Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Human Respiratory Syncytial Virus Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AstraZeneca Human Respiratory Syncytial Virus Drugs Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 AbbVie
6.2.1 AbbVie Corporation Information
6.2.2 AbbVie Description and Business Overview
6.2.3 AbbVie Human Respiratory Syncytial Virus Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AbbVie Human Respiratory Syncytial Virus Drugs Product Portfolio
6.2.5 AbbVie Recent Developments/Updates
6.3 GSK
6.3.1 GSK Corporation Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Human Respiratory Syncytial Virus Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 GSK Human Respiratory Syncytial Virus Drugs Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 Teva Pharmaceutical
6.4.1 Teva Pharmaceutical Corporation Information
6.4.2 Teva Pharmaceutical Description and Business Overview
6.4.3 Teva Pharmaceutical Human Respiratory Syncytial Virus Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Teva Pharmaceutical Human Respiratory Syncytial Virus Drugs Product Portfolio
6.4.5 Teva Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Respiratory Syncytial Virus Drugs Industry Chain Analysis
7.2 Human Respiratory Syncytial Virus Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Respiratory Syncytial Virus Drugs Production Mode & Process
7.4 Human Respiratory Syncytial Virus Drugs Sales and Marketing
7.4.1 Human Respiratory Syncytial Virus Drugs Sales Channels
7.4.2 Human Respiratory Syncytial Virus Drugs Distributors
7.5 Human Respiratory Syncytial Virus Drugs Customers
8 Human Respiratory Syncytial Virus Drugs Market Dynamics
8.1 Human Respiratory Syncytial Virus Drugs Industry Trends
8.2 Human Respiratory Syncytial Virus Drugs Market Drivers
8.3 Human Respiratory Syncytial Virus Drugs Market Challenges
8.4 Human Respiratory Syncytial Virus Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
